<?xml version='1.0' encoding='utf-8'?>
<document id="31898155"><sentence text="Comorbidity and polypharmacy in patients with breast cancer." /><sentence text="Cancer sufferers are aged ≥ 65 years, but research has focused infrequently on elderly patients with the majority of cancer" /><sentence text=" We aimed not only to determine the frequency of comorbidity and polypharmacy, but also to present the discrepiancies in elderly versus non-elderly patients with breast cancer" /><sentence text="" /><sentence text="A total of 352 female patients aged over 18 years, 252 non-elderly and 100 elderly, followed-up in the oncology department of a tertiary hospital between January 2016 and September 2019 were retrospectively screened" /><sentence text=" Demographic data, comorbidity and medications of the patients were recorded hospital data processing system" /><sentence text=" Polypharmacy was defined as the use of ≥ 5 different medications" /><sentence text="" /><sentence text="The most common four chronic diseases in both non-elderly and elderly groups were muscle-joint-bone disease, gastrointestinal diseases, diabetes mellitus and hypertension" /><sentence text=" The most common four prescribed drugs were NSAID, adjuvant endocrine therapy, PPI, and vitamin D or/and calcium in non-elderly group while those were ACEI-ARB, PPI, NSAID, and diuretics in elderly one"><entity charOffset="88-97" id="DDI-PubMed.31898155.s10.e0" text="vitamin D" /><entity charOffset="105-112" id="DDI-PubMed.31898155.s10.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.31898155.s10.e0" e2="DDI-PubMed.31898155.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31898155.s10.e0" e2="DDI-PubMed.31898155.s10.e1" /></sentence><sentence text=" The frequency of polypharmacy was 50% (n = 126) in the non-elderly patients and 74% (n = 74) in the elderly ones" /><sentence text=" These were considered statistically significant (p &lt; 0" /><sentence text="001)" /><sentence text=" The mean number of prescription medication categories reported was 5" /><sentence text="02 (SD = 2" /><sentence text="90; range 0-14) in non-elderly group whereas those was 6" /><sentence text="83 (SD = 3" /><sentence text="18; range 0-15) in elderly one (p &lt; 0" /><sentence text="001)" /><sentence text=" The mean of ages were 47" /><sentence text="9 years (without polypharmacy) and 51" /><sentence text="3 years (with polypharmacy) in non-elderly patients while those are, respectively, 70" /><sentence text="9 years and 74" /><sentence text="7 years in elderly ones" /><sentence text=" These were considered statistically significant (respectively; p = 0" /><sentence text="006, p = 0" /><sentence text="009)" /><sentence text="" /><sentence text="We first gained to raise awareness in the literature of comorbidity and polypharmacy in patients with breast cancer and to compare between the elderly and non-elderly participants" /><sentence text=" For the effectiveness of cancer treatment, importance in geriatric population, attention to drug-drug interaction, such studies should be considered during clinical practice" /><sentence text="" /></document>